



Sarai Keestra

By email

Reference: FOI -2021 Sarai Keestra

17 January 2022

Dear Sarai Keestra

FOI request: 15 December 2021

In reply to your questions:

Q1. Can you release your internal strategy, policy, or any kind of public statement regarding the technology transfer (e.g. licensing, patenting) of COVID-19 related health technologies?

Cambridge Enterprise does not have a strategy specific to licensing and patenting of COVID-19 related health technologies or health technologies. In line with our general approach each case is dealt with on its own merits but in a few cases, we have favoured publication of some concepts rather than taking a patent position.

Q2. Does the institution have a formal policy on licensing and patenting of health technologies? If yes, please provide a link or PDF to the relevant policy document.

No – see Q1

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since October 2020 in light of the pandemic?

Cambridge Enterprise Ltd. is a separate legal entity from the University and your request should be directed to the University. Cambridge Enterprise has considered a variety of initiatives such as the Open-COVID Pledge, early on in the C-19 pandemic. We concluded that while appropriate for some technologies it was inappropriate for others, so we had decided to apply our standard case by case approach.

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses (time period: September 2020-October 2021).

As with Q3 we cannot comment on technologies licensed by the University to whom you should direct your request. We can only comment on those licensed by Cambridge Enterprise which are listed below and are not covered by sII.43 (Commercial Interest) exemption of the FOIA.

Health Technology	Country of Licensing	Territory of Licence	Type of License (Exclusive or Non-Exclusive)
Liquid-liquid phase separation	USA	Worldwide	Exclusive



Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted (time period: September 2020-October 2021).

Grant/Issue date	PCT Number	Patent Number	Country of Filing
22/01/2021	PCT/GB2014/053385	1225439	Hong Kong
06/08/2021	PCT/GB2014/053385	11,029,315	United States
11/05/2021	PCT/GB2013/052757	2,888,858	Canada
02/02/2021	PCT/GB2013/052757	108636153	China
17/02/2021	PCT/GB2008/050944	2200740	Europe
17/02/2021	PCT/GB2008/050944	2200740	France
17/02/2021	PCT/GB2008/050944	60 2008 063 708.5	Germany
17/02/2021	PCT/GB2008/050944	2200740	Switzerland
17/02/2021	PCT/GB2008/050944	2200740	United Kingdom
03/02/2021	PCT/GB2016/051946	6823608	Japan
13/11/2020	PCT/GB2016/051946	3322967	Europe
13/11/2020	PCT/GB2016/051946	3322967	Austria
13/11/2020	PCT/GB2016/051946	3322967	Belgium
13/11/2020	PCT/GB2016/051946	3322967	Czech Republic
13/11/2020	PCT/GB2016/051946	3322967	Denmark
13/11/2020	PCT/GB2016/051946	3322967	Estonia
13/11/2020	PCT/GB2016/051946	3322967	Finland
13/11/2020	PCT/GB2016/051946	3322967	France
13/11/2020	PCT/GB2016/051946	3322967	Germany
13/11/2020	PCT/GB2016/051946	3322967	Greece
13/11/2020	PCT/GB2016/051946	3322967	Italy
13/11/2020	PCT/GB2016/051946	3322967	Ireland
13/11/2020	PCT/GB2016/051946	3322967	Luxembourg
13/11/2020	PCT/GB2016/051946	3322967	Netherlands
13/11/2020	PCT/GB2016/051946	3322967	Norway
13/11/2020	PCT/GB2016/051946	3322967	Portugal
13/11/2020	PCT/GB2016/051946	3322967	Poland
13/11/2020	PCT/GB2016/051946	3322967	Spain
13/11/2020	PCT/GB2016/051946	3322967	Sweden
13/11/2020	PCT/GB2016/051946	3322967	Switzerland
13/11/2020	PCT/GB2016/051946	3322967	Turkey
13/11/2020	PCT/GB2016/051946	3322967	United Kingdom
16/10/2020	PCT/GB2016/051946	107850521	China

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (<https://opencovidpledge.org/>) or any similar initiative that seeks to minimise intellectual property rights



barriers during the COVID-19 pandemic(since January 2020)? If yes, please specify. If the university has engaged in specific discussions with Open-COVID pledge, please provide files related to these meetings.

[See Q3](#)

Q7. Has the institution considered the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with either C-TAP and/or MPP please provide files related to these meetings.

[As with Q3 we cannot comment on what has been considered by the University to whom you should direct your request. Cambridge Enterprise has considered the WHO C-TAP/MPP initiative and had discussions with WHO. As with the Open-COVID pledge we do not consider it appropriate to all technologies. We also do not generally seek patent protection in territories outside the major OECD High Income Countries. Organisations in territories where technologies are not protected by IP right registration are free to exploit such technologies without a licence.](#)

Q8. Has the institution signed on to the AUTM COVID-19 Licensing Guidelines (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with AUTM on these guidelines please provide files related to these meetings.

[As with Q3 we cannot comment on what has been considered by the University to whom you should direct your request. Cambridge Enterprise has not signed on to the AUTM COVID-19 Licensing Guidelines.](#)

Q9. Has the institution with the WHO technology transfer hub during the pandemic (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with the WHO technology transfer hub please provide files related to these meetings.

[There appears to be a truncation of the question – could you please clarify](#)

Q10. Has the institution shared their best practices on the technology transfer of COVID-19 health technologies with other institutions? If yes, please specify. If the university has engaged in specific discussions with other universities on COVID-19 health technologies in the context of technology transfer, please provide files related to these meetings.

[As with Q3 we cannot comment on what has been considered by the University to whom you should direct your request. Cambridge Enterprise has not shared any practices on the technology transfer of COVID-19 health technologies with other Institutions.](#)

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request an internal review of this decision, you should contact us quoting the reference number above. Cambridge Enterprise would normally expect to receive your request for an internal review within 40 working days of the date of this letter and reserves the right not to review a decision where there has been undue delay in raising a complaint. If you are not content with the outcome of your review, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner cannot make a decision unless you have



exhausted the complaints procedure provided by Cambridge Enterprise. The Information Commissioner may be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF (<https://ico.org.uk/>).

Yours sincerely

Dr Paul Seabright

Deputy Director

paul.seabright@enterprise.cam.ac.uk

